IRF3 and type I interferons fuel a fatal response to myocardial infarction
Kevin R. King(Harvard University), Ralph Weissleder(Massachusetts General Hospital), Andrej Savol(Harvard University), Timothy P. Fitzgibbons(University of Massachusetts Chan Medical School), Ruslan I. Sadreyev(Harvard University), Yoshiko Iwamoto(Harvard University), Rainer H. Köhler(Massachusetts General Hospital), Richard P Ng(University of Calgary), Peter Libby(Harvard University), Katherine A. Fitzgerald(University of Massachusetts Chan Medical School), Sean P. Arlauckas(Massachusetts General Hospital), Timothy Mitchison(Harvard University), Matthias Nahrendorf(Massachusetts General Hospital), Jason D. Roh(Massachusetts General Hospital), Mark Kelly(University of Massachusetts Chan Medical School), Yuxiang Ye(Harvard University), Yuan Sun(Harvard University), Aaron D. Aguirre(Brigham and Women's Hospital)
Cited by 571
Related Papers
A clearer vision for in vivo imaging
|Nature Biotechnology|2001|3.8k
Inflammation in Atherosclerosis
|Arteriosclerosis Thrombosis and Vascular Biology|2012|3.7k
Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome
|Nature Immunology|2010|3k
Atherosclerosis
|Nature Reviews Disease Primers|2019|3k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k